Rise in Skin Infections, MRSA Suspected
Posted on: Tuesday, 29 July 2008, 21:00 CDT
U.S. researchers say they suspect a sharp rise in skin infections is due to methicillin-resistant Staphylococcus aureus, or MRSA.
Researchers at the University of California, San Francisco, say data from the National Center for Health Statistics for patient visits for skin infections from 1997 to 2005 show a rise from 8.6 nationwide to 14.2 million.
They also report an increase from 4.6 million to 9.6 million in visits for abscesses or cellulitis -- the hallmark sign of infections due to MRSA bacteria. The findings are published in the Archives of Internal Medicine.
The vast majority of that increase was attributable to visits for abscesses or cellulitis, study lead author Dr. Adam Hersh says in a statement. This shows that community-acquired MRSA infections are occurring nationwide and affect all subsets of the population. But there clearly are some subsets that are disproportionately affected, such as children.
The number of visits for abscesses or cellulitis almost tripled in children during the study period.
Another increase in visits for abscesses or cellulitis was among patients who visit emergency rooms in urban areas at so-called safety net hospitals -- where many patients receive Medicaid or are uninsured. Among these patients, the rate nearly quadrupled.
Source: United Press International
Related Articles
- New Survey Highlights Growing Concern About Risk of Infection in Cancer Patients and Emerging Antibiotic Resistance
- CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
- Next Generation CyberKnife Increases Patient Throughput at Philadelphia CyberKnife
- RTOG and US Oncology Partner to Increase Patient Access to Cancer Trials
- Radiation Therapy Oncology Group and US Oncology Enter Collaboration to Increase Patient Access to National Clinical Trials
- Improving Medication Adherence: CD-ROM Webinar on Practical Strategies to Increase Patient Compliance
- RMH Selects Medhost Software to Increase Patient Safety
- National Study Demonstrates Gentiva(R) Cardiopulmonary's Ability to Increase Patient Functionality, and Reduce Hospitalizations and Emergency Room Visits
- FDA Approves New Indication for INVANZ(R) (Ertapenem) for the Treatment of Moderate to Severe Complicated Foot Infection in Diabetic Patients Without Osteomyelitis
- Nektar Announces Inhaled Amphotericin B Product in Human Clinical Trials for Preventing Fatal Pulmonary Fungal Infections in Immunosuppressed Patients
User Comments (0)
RSS Feeds